HOUSTON, June 25, 2020 /PRNewswire/ -- Soliton, Inc.,
(Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device
company with a novel and proprietary platform technology, today
announced that it intends to offer shares of its common stock in an
underwritten public offering. In addition, Soliton intends to grant
the underwriters a 30-day option to purchase up to an additional
15% of the number of shares of its common stock offered in the
public offering. The proposed offering is subject to market and
other conditions, and there can be no assurance as to whether or
when the offering may be completed, or as to the actual size or
terms of the offering.
Cantor Fitzgerald & Co. is acting as the sole book-running
manager for the proposed offering.
The shares of common stock are being offered by the Company
pursuant to a registration statement previously filed with and
declared effective by the Securities and Exchange Commission (the
"SEC"). The offering will be made only by means of a prospectus,
consisting of a prospectus supplement and an accompanying
prospectus. A preliminary prospectus supplement and an accompanying
prospectus relating to the offering will be filed with the SEC and
will be available on the SEC's website located at
http://www.sec.gov. Copies of the preliminary prospectus supplement
and the accompanying prospectus, when filed with the SEC, may also
be obtained from Cantor Fitzgerald & Co., 499 Park Avenue, 6th
Floor, New York, NY 10022, Attn:
Capital Markets Department, or by email at
prospectus@cantor.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities, in any state or jurisdiction in
which such an offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any
such state or jurisdiction.
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from MD Anderson. The
Company's first FDA cleared commercial product will use rapid
pulses of acoustic shockwaves as an accessory to lasers for the
removal of unwanted tattoos. The Company is based in Houston, Texas, and is actively engaged in
bringing the Rapid Acoustic Pulse ("RAP") device to the market.
Soliton has completed a clinical study using the RAP device to
improve the appearance of cellulite and is investigating potential
additional capabilities of the RAP technology in preclinical
testing, including the potential to assist existing fat reduction
technology in the reduction of fat. The device is currently
cleared in the United States only
for use in tattoo removal and is not yet cleared for use to address
cellulite.
Forward-Looking Statements
This press release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, Section
21E of the Securities Exchange Act of 1934 and the Private
Securities Litigation Reform Act of 1995, which statements involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, whether the Company will be
successful in completing the proposed offering. These statements
relate to future events, future expectations, plans and prospects.
Although Soliton believes that the expectations reflected in such
forward-looking statements are reasonable as of the date made,
actual results or outcomes may prove to be materially different
from the expectations expressed or implied by such forward-looking
statements. Soliton has attempted to identify forward-looking
statements by terminology including ''believes,'' ''estimates,''
''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,''
''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' "would,"
''should,'' ''approximately'' or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. These statements are only predictions
and involve known and unknown risks, uncertainties, and other
factors, including those discussed in our filings with the SEC,
including under the heading " Risk Factors" in our Form 10-K for
year ended December 31, 2019 filed
with the SEC and as updated in our Form 10-Q filings and in our
other filings with the SEC. Any forward-looking statements
contained in this release speak only as of its date. Soliton
undertakes no obligation to update any forward-looking statements
contained in this release to reflect events or circumstances
occurring after its date or to reflect the occurrence of
unanticipated events.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/soliton-announces-proposed-public-offering-of-common-stock-301084006.html
SOURCE Soliton, Inc.